AKT1 and Miyoshi myopathy: As a consequence, the combination of miRNA-29b and bortezomib may decrease bortezomib-resistance, increasing the sensitivity of MM cells to the drug resulting in enhanced apoptosis and inhibition of the PI3K-AKT signaling pathway [94].